[{"id":"0d632197-009b-4cc8-8b15-f154cec2fe79","acronym":"ACCIO","url":"https://clinicaltrials.gov/study/NCT04267848","created_at":"2021-01-18T20:44:14.334Z","updated_at":"2025-02-25T12:37:33.994Z","phase":"Phase 3","brief_title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial","source_id_and_acronym":"NCT04267848 - ACCIO","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • pemetrexed • Pembroria (pembrolizumab biosimilar) • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 1210","initiation":"Initiation: 06/16/2020","start_date":" 06/16/2020","primary_txt":" Primary completion: 12/15/2025","primary_completion_date":" 12/15/2025","study_txt":" Completion: 12/15/2025","study_completion_date":" 12/15/2025","last_update_posted":"2025-02-24"},{"id":"67ef8418-6d77-4d74-95d8-80f63ef20ed4","acronym":"SWOG S2001","url":"https://clinicaltrials.gov/study/NCT04548752","created_at":"2021-01-18T21:45:16.998Z","updated_at":"2025-02-25T12:27:43.236Z","phase":"Phase 2","brief_title":"Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations","source_id_and_acronym":"NCT04548752 - SWOG S2001","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • cisplatin • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 02/22/2021","start_date":" 02/22/2021","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-24"},{"id":"7bf4c100-c992-4e7a-9ed8-b32c4d26ea43","acronym":"SWOG 1512","url":"https://clinicaltrials.gov/study/NCT02775851","created_at":"2021-01-18T13:36:44.518Z","updated_at":"2025-02-25T12:26:29.443Z","phase":"Phase 2","brief_title":"Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02775851 - SWOG 1512","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD8 • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 02/06/2017","start_date":" 02/06/2017","primary_txt":" Primary completion: 04/14/2023","primary_completion_date":" 04/14/2023","study_txt":" Completion: 05/15/2026","study_completion_date":" 05/15/2026","last_update_posted":"2025-02-24"},{"id":"e3b4bad8-8656-47cc-998e-a5d2146657b6","acronym":"ALCHEMIST Screening","url":"https://clinicaltrials.gov/study/NCT02194738","created_at":"2021-01-18T10:15:39.910Z","updated_at":"2025-02-25T12:26:10.714Z","phase":"","brief_title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","source_id_and_acronym":"NCT02194738 - ALCHEMIST Screening","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement","tags":["EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • cisplatin • Xalkori (crizotinib) • erlotinib • carboplatin • gemcitabine • paclitaxel • docetaxel • Mektovi (binimetinib) • pemetrexed • sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed) • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 8300","initiation":"Initiation: 09/26/2014","start_date":" 09/26/2014","primary_txt":" Primary completion: 09/28/2026","primary_completion_date":" 09/28/2026","study_txt":" Completion: 09/28/2026","study_completion_date":" 09/28/2026","last_update_posted":"2025-02-24"},{"id":"be73eee7-8633-483e-a581-812fd81e01b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04929041","created_at":"2021-06-18T23:52:29.992Z","updated_at":"2025-02-25T14:02:22.824Z","phase":"Phase 2/3","brief_title":"Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative","source_id_and_acronym":"NCT04929041","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • ALK mutation","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed • ABP 206 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 427","initiation":"Initiation: 10/07/2022","start_date":" 10/07/2022","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-19"},{"id":"405369f8-6c34-4eaf-86cd-9b205b8bd8af","acronym":"ETCTN 10183","url":"https://clinicaltrials.gov/study/NCT03854474","created_at":"2021-01-18T19:01:24.885Z","updated_at":"2025-02-25T15:18:02.909Z","phase":"Phase 1/2","brief_title":"Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma","source_id_and_acronym":"NCT03854474 - ETCTN 10183","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" EZH2 mutation","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • Tazverik (tazemetostat) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/18/2019","start_date":" 11/18/2019","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-12"},{"id":"696d727b-575b-4b42-9ab7-71058751cfe0","acronym":"NCI-2021-13902","url":"https://clinicaltrials.gov/study/NCT05172258","created_at":"2021-12-29T13:53:34.637Z","updated_at":"2025-02-25T16:32:39.281Z","phase":"Phase 2","brief_title":"Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck","source_id_and_acronym":"NCT05172258 - NCI-2021-13902","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ipatasertib (RG7440) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 07/26/2022","start_date":" 07/26/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-07"},{"id":"28981dd2-d823-4640-b93e-9a28bd46c20d","acronym":"AMBASSADOR","url":"https://clinicaltrials.gov/study/NCT03244384","created_at":"2021-01-18T16:01:48.076Z","updated_at":"2025-02-25T16:36:58.445Z","phase":"Phase 3","brief_title":"Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer","source_id_and_acronym":"NCT03244384 - AMBASSADOR","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 739","initiation":"Initiation: 11/03/2017","start_date":" 11/03/2017","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-06"},{"id":"343860fb-1c41-454c-a2e5-97b25f553d79","acronym":"","url":"https://clinicaltrials.gov/study/NCT02954874","created_at":"2021-01-18T14:30:57.547Z","updated_at":"2025-02-25T16:44:03.478Z","phase":"Phase 3","brief_title":"Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer","source_id_and_acronym":"NCT02954874","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PD-L1 • ER • PGR • CD4","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • PD-L1 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1155","initiation":"Initiation: 01/18/2017","start_date":" 01/18/2017","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2025-02-06"},{"id":"3f5aa33e-06f6-48ab-8a9d-748f65a29841","acronym":"NRG GY020","url":"https://clinicaltrials.gov/study/NCT04214067","created_at":"2021-01-18T20:31:12.388Z","updated_at":"2025-02-25T16:44:47.600Z","phase":"Phase 3","brief_title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer","source_id_and_acronym":"NCT04214067 - NRG GY020","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 04/09/2020","start_date":" 04/09/2020","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2025-02-06"},{"id":"57381c24-31ec-4c63-b601-61888dd1102a","acronym":"EA5163","url":"https://clinicaltrials.gov/study/NCT03793179","created_at":"2021-01-18T18:45:20.609Z","updated_at":"2025-02-25T16:37:19.034Z","phase":"Phase 3","brief_title":"Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03793179 - EA5163","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • BRAF • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation","tags":["EGFR • PD-L1 • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • pemetrexed • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 04/05/2019","start_date":" 04/05/2019","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-06"},{"id":"64d1ef99-04c4-4d5a-830b-60a55b2be129","acronym":"","url":"https://clinicaltrials.gov/study/NCT05422794","created_at":"2022-06-22T01:54:45.793Z","updated_at":"2025-02-25T16:39:06.146Z","phase":"Phase 1","brief_title":"Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer","source_id_and_acronym":"NCT05422794","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • albumin-bound paclitaxel • ZEN-3694 • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 05/18/2023","start_date":" 05/18/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"93546d33-d260-437a-9cd5-b7629d9d588d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708418","created_at":"2023-04-01T19:06:08.459Z","updated_at":"2025-02-25T16:38:10.265Z","phase":"Phase 2","brief_title":"A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma","source_id_and_acronym":"NCT04708418","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • vidutolimod (CMP-001) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/15/2021","start_date":" 10/15/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-06"},{"id":"67575df3-fe79-49cd-97ab-2aa59bfde6c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02359565","created_at":"2021-01-18T11:13:52.172Z","updated_at":"2025-02-25T16:58:45.335Z","phase":"Phase 1","brief_title":"Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma","source_id_and_acronym":"NCT02359565","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • TMB","pipe":" | ","alterations":" TMB-H","tags":["PD-L1 • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 06/03/2015","start_date":" 06/03/2015","primary_txt":" Primary completion: 12/21/2025","primary_completion_date":" 12/21/2025","study_txt":" Completion: 12/21/2025","study_completion_date":" 12/21/2025","last_update_posted":"2025-02-03"},{"id":"d2101305-ed21-4d8c-a684-029721d03d01","acronym":"NCI-2022-03215","url":"https://clinicaltrials.gov/study/NCT05353439","created_at":"2022-04-29T11:55:38.458Z","updated_at":"2025-02-25T16:26:50.630Z","phase":"Phase 1","brief_title":"Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer","source_id_and_acronym":"NCT05353439 - NCI-2022-03215","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tazverik (tazemetostat) • topotecan • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 60","initiation":"Initiation: 07/27/2022","start_date":" 07/27/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2025-01-28"},{"id":"66fbb1c2-a237-4e6c-8712-7eb2a2917dab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03030378","created_at":"2021-01-29T07:14:02.376Z","updated_at":"2024-07-02T16:34:37.122Z","phase":"Phase 1","brief_title":"Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors","source_id_and_acronym":"NCT03030378","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 05/30/2018","start_date":" 05/30/2018","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-07"},{"id":"80611a75-8e50-4af0-8595-0b4412326e20","acronym":"","url":"https://clinicaltrials.gov/study/NCT04576091","created_at":"2021-01-18T21:50:45.107Z","updated_at":"2024-07-02T16:34:37.303Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer","source_id_and_acronym":"NCT04576091","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD8 • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • elimusertib (BAY 1895344) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 07/06/2022","start_date":" 07/06/2022","primary_txt":" Primary completion: 11/27/2024","primary_completion_date":" 11/27/2024","study_txt":" Completion: 11/27/2024","study_completion_date":" 11/27/2024","last_update_posted":"2024-06-07"},{"id":"068c80f1-b744-42e6-bb47-84aa54ab2e3c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05673200","created_at":"2023-01-06T16:59:14.142Z","updated_at":"2024-07-02T16:34:38.142Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT05673200","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • paclitaxel • Inqovi (decitabine/cedazuridine) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 24","initiation":"Initiation: 09/25/2023","start_date":" 09/25/2023","primary_txt":" Primary completion: 02/23/2027","primary_completion_date":" 02/23/2027","study_txt":" Completion: 02/23/2027","study_completion_date":" 02/23/2027","last_update_posted":"2024-06-05"},{"id":"af5b2b8c-e254-4a25-b607-944acb5d90e8","acronym":"SWOG S1404","url":"https://clinicaltrials.gov/study/NCT02506153","created_at":"2021-01-18T12:05:51.420Z","updated_at":"2024-07-02T16:35:01.870Z","phase":"Phase 3","brief_title":"Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery","source_id_and_acronym":"NCT02506153 - SWOG S1404","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • Intron A (interferon α-2b) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1345","initiation":"Initiation: 11/10/2015","start_date":" 11/10/2015","primary_txt":" Primary completion: 09/15/2023","primary_completion_date":" 09/15/2023","study_txt":" Completion: 01/23/2025","study_completion_date":" 01/23/2025","last_update_posted":"2024-05-22"},{"id":"74a856b5-259a-4d5c-9166-0007d61a1cb7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05570825","created_at":"2022-10-07T15:08:08.992Z","updated_at":"2024-07-02T16:35:05.631Z","phase":"Phase 2","brief_title":"SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05570825","lead_sponsor":"University of Washington","biomarkers":" PD-L1 • ALK • RET • ROS1","pipe":" | ","alterations":" PD-L1 expression • RET fusion • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement","tags":["PD-L1 • ALK • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • RET fusion • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SX-682 • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/06/2023","start_date":" 04/06/2023","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-05-07"},{"id":"1709c9a1-ac1e-4f56-aabe-efd83c0933f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03126630","created_at":"2021-01-18T15:24:22.600Z","updated_at":"2024-07-02T16:35:23.903Z","phase":"Phase 1/2","brief_title":"Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma","source_id_and_acronym":"NCT03126630","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • MSLN","pipe":" | ","alterations":" PD-L1 expression • MSLN expression","tags":["PD-L1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • anetumab ravtansine (BAY 94-9343) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 10/04/2018","start_date":" 10/04/2018","primary_txt":" Primary completion: 07/08/2023","primary_completion_date":" 07/08/2023","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2024-01-10"},{"id":"277cef5a-ecd7-472f-ac18-a91f7891a25f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02595866","created_at":"2021-01-18T12:35:54.152Z","updated_at":"2024-07-02T16:35:30.462Z","phase":"Phase 1","brief_title":"Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer","source_id_and_acronym":"NCT02595866","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • BRAF • ALK • ROS1 • CD4","pipe":" | ","alterations":" BRAF V600 • ALK mutation • ROS1 mutation","tags":["PD-L1 • BRAF • ALK • ROS1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • ALK mutation • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 04/04/2016","start_date":" 04/04/2016","primary_txt":" Primary completion: 10/04/2023","primary_completion_date":" 10/04/2023","study_txt":" Completion: 10/11/2024","study_completion_date":" 10/11/2024","last_update_posted":"2023-11-03"},{"id":"0ed959af-c2b5-458e-b542-28311d0168e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03063632","created_at":"2021-01-18T15:05:12.923Z","updated_at":"2024-07-02T16:35:31.715Z","phase":"Phase 2","brief_title":"Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma","source_id_and_acronym":"NCT03063632","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNG • CTAG1B","pipe":" | ","alterations":" CTAG1B expression","tags":["IFNG • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Actimmune (interferon gamma-1 b) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 12/14/2017","start_date":" 12/14/2017","primary_txt":" Primary completion: 04/08/2021","primary_completion_date":" 04/08/2021","study_txt":" Completion: 03/14/2023","study_completion_date":" 03/14/2023","last_update_posted":"2023-10-25"},{"id":"0c2b46a3-7293-4bb1-9aed-4cb904481f9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05986331","created_at":"2023-08-14T15:09:54.144Z","updated_at":"2024-07-02T16:35:36.281Z","phase":"Phase 3","brief_title":"Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma","source_id_and_acronym":"NCT05986331","lead_sponsor":"Biocad","biomarkers":" PROCR","pipe":"","alterations":" ","tags":["PROCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 366","initiation":"Initiation: 07/18/2022","start_date":" 07/18/2022","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-09-21"}]